Pharma makes steady billions from chronic meds people take for life — diabetes, cholesterol, arthritis — not one-time fixes. Ongoing prescriptions = predictable revenue. R&D often targets “safe” profitable drugs instead of risky breakthrough cures. Meanwhile, diseases affecting poorer populations get less investment because the ROI is lower.
That doesn’t prove companies hide cures. But the incentive structure? It clearly favors lifelong customers over one-time solutions.